Investigating how copper transport via SLC31A1 regulates pro-inflammatory Th17 cell activity, this project uncovers a novel link between immune cell metabolism and MS, pointing toward new therapeutic targets.
Engineering HLA-DQ–specific CAR Tregs to selectively suppress anti-donor immune responses at sites of graft inflammation, this project seeks a more precise, durable alternative to broad immunosuppression in transplantation.
Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.
Systematically identifying and validating repurposed FDA-approved drugs for over 160 autoimmune diseases using AI, knowledge graphs, and high-throughput experimental screening.
Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.
Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
Developing VCAM-1-targeted lipid nanoparticles delivering IL-10 mRNA to reduce neuroinflammation and improve outcomes after intracerebral hemorrhage.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
